Allient Inc. heads into its Q1 2026 earnings call today with a striking piece of context: virtually every named executive sold shares on April 1, just weeks before the stock surged to a new high.
The insider activity is the most telling signal going into this print. CEO Richard Warzala sold 22,956 shares at $61.82 — a $1.4 million disposal — on April 1. The CFO, CTO, and multiple vice presidents all sold on the same date. A vice president sold an additional 6,000 shares on March 27. In aggregate, insiders were net sellers of more than 36,000 shares in the 90-day window, representing roughly $2.2 million in proceeds. The stock has since rallied another 25% from those sale prices to close at $77.52 on Wednesday. That gap between where insiders exited and where the stock trades now frames the key tension heading into today's release.
Short interest is not where the drama lies. SI runs at 4.5% of the free float — meaningful but not extreme — and has been essentially flat over the past month, drifting up just under 6%. Borrow conditions are completely relaxed: cost to borrow is below 0.5%, and the lending market is wide open, with availability posing no constraint on new short positions. The ORTEX short score, at 44, places Allient squarely in the middle of the universe — no squeeze pressure, no elevated bear conviction. Options traders are equally composed, with the put/call ratio at 0.14, barely above its 20-day average and well short of any defensive extreme.
The bull case rests on a stock that has gained 45% year-to-date and an estimated EPS of $2.63 on roughly $584 million in revenue — a business that analysts covering the name have grown steadily more optimistic about. Roth Capital raised its price target to $69 in mid-March. JP Morgan initiated with Neutral and a $60 target last October. Both targets are now well below the current price of $77.52, which means even the bulls on the Street have been outpaced by the tape. The stock trades at a P/E of close to 28x and an EV/EBITDA of 16.8x — multiples that have expanded roughly 28% over the past month alone, meaning valuation has re-rated sharply into the print.
Today's earnings call is therefore less about whether Allient can grow and more about whether management's operational delivery — and guidance — can justify a valuation that has moved well ahead of Wall Street's published targets while those same executives were quietly taking money off the table.
See the live data behind this article on ORTEX.
Open ALNT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
